title: Clinical determinants of aspirin resistance in diabetes.
abstract: Recent studies indicate that not all diabetic subjects benefit from aspirin therapy. Our objective is to characterize diabetic subjects with aspirin resistance using urine thromboxane, and VerifyNow measures. Our results suggest that cardiovascular disease, microalbuminuria, poor diabetes control, and increased waist circumference help identify aspirin resistance in diabetes.
authors: Department of Medicine, Division of Endocrinology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA. hyassine@email.arizona.edu
authors: Hussein N
authors: HN
authors: Yassine
authors: Grace
authors: G
authors: Davis-Gorman
authors: Craig S
authors: CS
authors: Stump
authors: Stephen S
authors: SS
authors: Thomson
authors: Justin
authors: J
authors: Peterson
authors: Paul F
authors: PF
authors: McDonagh
mesh_terms: D000419:Albuminuria / Q000652:urine; D001241:Aspirin / Q000627:therapeutic use*; D015331:Cohort Studies; D003925:Diabetic Angiopathies / Q000097:blood / Q000517:prevention & control* / Q000652:urine; D004351:Drug Resistance; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine; D055105:Waist Circumference
chemical_list: D001241:Aspirin; D006442:Glycated Hemoglobin; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; C517652:hemoglobin A1c protein, human; C049235:11-dehydro-thromboxane B2